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LETTER TO THE EDITOR
Efficacy of Vinorelbine
in the Second-Line
Setting and Beyond in
Non-small Cell Lung
Cancer
To the Editor
We read with great interest Noble
et al.’s article “Second-Line or Subse-
quent Systemic Therapy for Recurrent
or Progressive Non-Small Cell Lung
Cancer: A Systematic Review and Prac-
tice Guideline” in the November issue
of the Journal of Thoracic Oncology.1
Chemotherapy beyond second line for
advanced non-small cell lung cancer
(NSCLC) is traditionally considered to
have very little impact on overall survival.
The Food and Drug Administra-
tion has approved docetaxel, perme-
trexed, and erlotinib for the treatment of
advanced NSCLC in the second-line set-
ting.2 Currently, single-agent vinorel-
bine is not often used in the second-line
setting based on the results from the
phase III TAX 320 trial.3 We conducted
a retrospective review of all patients
with NSCLC treated with vinorelbine at
Washington University School of Med-
icine/Alvin J. Siteman Cancer Center
from 1999 to 2004. We identified 34
patients receiving salvage chemotherapy
with vinorelbine for the treatment of
advanced NSCLC. It was administered
as second-line chemotherapy for 8 pa-
tients (24%), third line for 13 patients
(38%), and fourth line for 13 patients
(38%). Twenty- nine patients (85%) had
prior exposure to platinum agents, 12
(35%) had previous exposure to do-
cetaxel, and none had received pem-
etrexed. The median number of cycles
of vinorelbine was three (range, one to
six). Of the 34 patients, 33 received
single-agent vinorelbine, and 1 patient
received it in combination with gemcit-
abine. The median progression-free sur-
vival time was 5.6 months (95% CI,
2.98 to 7.38). The median overall sur-
vival time was 10.7 months (95% CI,
7.38 to 18.22), and 1-year overall sur-
vival was 44%. Partial response (PR)
was reported in 1 patient (3%), stable
disease in 13 patients (38%), progres-
sive disease in 16 (47%), and unknown
in 4 (12%). No complete response was
reported.
Previous studies on vinorelbine
monotherapy in this setting have shown
highly variable rates (0% and 50%).4,5
In this report, the objective response rate
for vinorelbine is low (3%). However,
the progression-free survival of 5.6
months observed in this study is quite
meaningful. Most patients (76%) had
received vinorelbine in the third-line
setting or beyond. The median survival
of 10.4 months and 1-year survival of
44% in this study suggests that vinorel-
bine has a role to play beyond the first-line
setting for some patients with advanced
NSCLC. Clearly, significant advances in
lung cancer can only happen with a better
understanding of molecular pathogenesis
and development of novel agents.
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